NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Patritumab deruxtecan|DRUG: Chemotherapy|DRUG: Letrozole
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Daiichi Sankyo